Calibration of transition probabilities to model survival of adjuvant trastuzumab for early breast cancer in Indonesia.

ABSTRACT:

Objectives

Cost-effectiveness models fully informed by real-world epidemiological parameters yield the best results, but they are costly to obtain. Model calibration using real-world data/evidence (RWD/E) on routine health indicators can provide an alternative to improve the validity and acceptability of the results. We calibrated the transition probabilities of the reference chemotherapy treatment using RWE on patient overall survival (OS) to model the survival benefit of adjuvant trastuzumab in Indonesia.

Methods

A Markov model comprising four health states was initially parameterized using the reference-treatment transition probabilities, obtained from published international evidence. We then calibrated these probabilities, targeting a 2-year OS of 86.11 percent from the

SUBMITTER: Rahadi A 

PROVIDER: S-EPMC11955306 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature